Issued: Mar-17-2017



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product Name: Humira (R) (Adalimumab) Citrate Free

List Number: 0554; 0243

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended use: Pharmaceuticals

1.3. Details of the supplier of the safety data sheet

Supplier: AbbVie Inc.

1 North Waukegan Road North Chicago, IL 60064

USA

+1-847-932-7900

E-mail Address: AbbVie.SDS@abbvie.com

1.4. Emergency telephone number

Emergency Telephone: CHEMTREC: 1(800) 424-9300 (in USA and Canada)

or +1-703-527-3887 (international)

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

Classification according to EU Directives 67/548/EEC or 1999/45/EC

2.2. Label elements

Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

2.3. Other hazards

Not determined

SECTION 3: Composition/information on ingredients

Chen	nical Name	Weight-%	EINECS/ELINCS	EEC Classification	EU - GHS	REACH Reg. No
		_	Number		Substance	_
					Classification	

Mar-17-2017 Issued:

Water	80-90	Present	Not Hazardous*	No data available
7732-18-5				
Adalimumab	5-10	NA	Not Hazardous*	No data available
L-02-3126				
Mannitol	1-5	Present	Not Hazardous*	No data available
69-65-8				
Polysorbate 80	<1	NA	Not Hazardous*	No data available
9005-65-6				

Not Hazardous* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16 For the full text of the H-Statements mentioned in this Section, see Section 16

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic/supportive care as necessary.

Remove from source of exposure. If signs of toxicity occur, seek medical **Ingestion:**

attention. Provide symptomatic/supportive care as necessary.

Protection of First-aiders: Use personal protective equipment

4.2 Most important symptoms and effects, both acute and delayed

Signs and Symptoms No signs and symptoms from occupational exposure are known. Clinical data

> suggests the following: headaches, coughing, rash, dizziness, nasal discharge, fever, gastrointestinal upset, leucopenia, variable cardiovascular system effects.

by Exposure

Medical Conditions Aggravated None known from occupational exposure. Data suggest any pre-existing ailments

in the following organs: gastrointestinal system, cardiovascular system, lymphatic

system, or hematopoietic system.

4.3. Indication of any immediate medical attention and special treatment needed

Notes To Physician: Treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable Extinguishing Media: Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

Issued: Mar-17-2017

5.2. Special hazards arising from the substance or mixture

Special Exposure Hazards: Not determined

5.3. Advice for firefighters

Protective Equipment and Precautions for Firefighters:

As in any fire, wear self-contained breathing apparatus and full protective gear

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal Precautions: For personal protection see section 8.

6.2. Environmental precautions

Environmental Precautions: Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Disinfect with 10% (v/V) bleach solution. Dispose of material as directed in

Section 13.

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions.

7.3. Specific end use(s)

Recommended use: Pharmaceuticals

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Exposure limits:

Chemical Name	Employee Exposure Limit	Skin Notation
Water 7732-18-5	Not applicable	None
Adalimumab L-02-3126	200 mcg/m ³	None
Mannitol 69-65-8	Not applicable	None
Polysorbate 80 9005-65-6	Not applicable	None

Issued: Mar-17-2017

8.2. Exposure controls

Engineering Controls: No special provisions are required under normal conditions. When handling bulk

formulation, use in a well-ventilated area.

Respiratory Protection: Respiratory protection is not needed during normal product use. When handling

the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be

worn when exposures are expected to exceed the applicable limits.

Eyes: Eye protection not needed during typical product use conditions. Wear eye

protection as appropriate when handling the bulk formulation.

Gloves: Gloves not required during normal product use conditions. Wear impervious

gloves when handling the bulk formulation.

Other PPE Data: Wear appropriate body coverings if contact may occur.

Environmental Exposure

Controls:

Not determined

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance: Clear/Colorless Solution

Odor: Odorless.
Odor Threshold: Not determined

pH: 4.7-5.7

Not determined **Boiling Pt.** @ 760 mm **Hg** (°C): **Melting/Freezing Point (°C):** Not determined Flash Point (°C): Not determined **Evaporation Rate at 20°C:** Not determined Flammability (Solid): Not determined **Lower Explosive Limit:** Not determined **Upper Explosive Limit:** Not determined **Vapor Pressure (mm Hg):** Not determined Vapor Density (Air = 1): Not determined Density, g / mL: 1.01-1.05 **Specific Gravity:** Not determined

Solubility(ies): Freely soluble in: water.

Partition coefficient: Not determined

n-octanol/water

Autoignition Temp. (°C): Not determined **Decomposition temperature** Not determined

(°C):

Viscosity (centipoise):Not determinedExplosion Severity:Not determinedOxidizer Properties:Not determined

9.2. Other information

Not determined

Issued: Mar-17-2017

SECTION 10: Stability and reactivity

10.1. Reactivity

Not determined

10.2. Chemical stability

Stable under normal conditions

10.3. Possibility of hazardous reactions

Hazardous reactions: Not determined

10.4. Conditions to avoid

Not determined

10.5. Incompatible materials

Not determined

10.6. Hazardous decomposition products

Not determined

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Routes of Exposure:

Oral: Yes
Dermal: Yes
Inhalation: Unlikely

Acute Toxicity - Oral: Data for component (s) given below:

Chemical Name	Acute Test	Value	Units	Species
Mannitol 69-65-8	LD50 =	13,500-22,000	mg/kg	Mice Rats
Polysorbate 80 9005-65-6	LD50 =	25,000 - 36,570	mg/kg	Mice Rats

Acute Toxicity - Dermal: Not determined

Acute Toxicity - Inhalation: Not determined

Other Toxicology Data: Data for component (s) given below:

Chemical Name	Test Type	Value	Units	Species	Comments
Adalimumab	ALD (iv) >	898	mg/kg	Rats	None
L-02-3126				Mice	

Corrosivity: Not determined

Dermal Irritation: Active Ingredient(s): Produced little or no skin irritation in animals.

Eye irritation: Not determined

Issued: Mar-17-2017

Sensitization: Not determined

Toxicokinetics/Metabolism: Not determined

Target Organ Effects Data for component (s) given below:

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Adalimumab L-02-3126		Mice Liquid Monkeys	> 82.9	mg/kg/wk	Intravenous	Variable exposure periods
	system					
Mannitol	Eyes Kidney	Rats Mice	25,000	ppm	Oral Diet	Repeat dose study
69-65-8						(ies).

Reproductive Effects Active Ingredient : Animal testing did not show any effects on fetal development

Animal testing did not show any effects on fertility

Chemical Name	Species	Dosage	Units	Route	Duration
Adalimumab	Monkeys	< 100	mg/kg/wk	Intravenous	Variable Treatment
L-02-3126			1		Regimens

Carcinogenicity Not determined

Mutagenicity: Data for component (s) given below:

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Adalimumab L-02-3126	Negative	Negative	No Data.	No Data.

Aspiration hazard: Not determined

Notes:

1. ALD: Approximate lethal dosage

2. LC50: Concentration in air that produces 50% mortality3. LD50: Oral or dermal dosage that produces 50% mortality

SECTION 12: Ecological information

12.1. Toxicity

Not determined

12.2. Persistence and degradability

Not determined

12.3. Bioaccumulative potential

Not determined

12.4. Mobility in soil

Not determined

12.5. Results of PBT and vPvB assessment

Chemical safety report is not required for this substance/product.

12.6. Other adverse effects

Issued: Mar-17-2017

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.
- 2. LC50: Concentration in water that produces 50% mortality in fish.
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local

regulations.

SECTION 14: Transport information

ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

14.1. UN number
14.2. Proper shipping name:
14.3. Hazard class:
14.4. Packing group:
14.5. Environmental hazard:
14.6. Special provisions:
14.7. Transport in bulk
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

according to Annex II of MARPOL 73/78 and the IBC

Code:

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Water	Present	X	X	Not listed	X
7732-18-5					
Adalimumab	-	-	-	Not listed	-
L-02-3126					
Mannitol	Present	X	X	Not listed	X
69-65-8					
Polysorbate 80	-	X	X	Not listed	X
9005-65-6					

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Water 7732-18-5	-	-	X	X	Present	
Adalimumab L-02-3126	-	-	-	-	-	
Mannitol 69-65-8	Present	Present	X	X	Present	
Polysorbate 80 9005-65-6	Present	Present	X	X	Present	

Issued: Mar-17-2017

Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

Carcinogenicity Rating:

Chemical Name	Weight-%	NTP:	IARC:	ACGIH:
Water	80-90	Not listed	Not listed	Not listed
Adalimumab	5-10	Not listed	Not listed	Not listed
Mannitol	1-5	Not listed	Not listed	Not listed
Polysorbate 80	<1	Not listed	Not listed	Not listed

SARA 313 Information

Chemical Name	Weight-%	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Water	80-90	No	Not applicable	Not applicable
Adalimumab	5-10	No	Not applicable	Not applicable
Mannitol	1-5	No	Not applicable	Not applicable
Polysorbate 80	<1	No	Not applicable	Not applicable

RCRA Status: Not determined

Proposition 65 Status: Does not contain chemicals known to the state of California to cause cancer or

reproductive harm.

WHMIS Hazard Class Exempt

Notes:

- 1. SARA = Superfund Amendments and the Reauthorization Act.
- 2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
- 3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
- 4. TSCA = Toxic Substances Control Act.
- 5. EC = European Community.
- 6. WHMIS = Canadian Workplace Hazardous Materials Information System.
- 7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

SECTION 16: Other information

Document Authored By: Occupational and Environmental Toxicology

Issued: Mar-17-2017

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.